Elicera Therapeutics
6.63 SEK
+2.00 %
Less than 1K followers
ELIC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+2.00 %
+5.91 %
-7.40 %
+5.24 %
+297.01 %
+272.47 %
+61.71 %
-
+6.94 %
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.
Read moreMarket cap
321.79M SEK
Turnover
1.03M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
13.2
2026
Annual report '25
5.5
2026
General meeting '26
5.5
2026
Interim report Q1'26
All
Research
Press releases
3rd party
ShowingAll content types
BioStock: Extensive positive media coverage for Elicera in Q3
Elicera Therapeutics AB (publ) Interim 1 January - 30 September 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools